CARL vs GMED

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

CARL

50.9
AI Score
VS
CARL Wins

GMED

50.7
AI Score

Investment Advisor Scores

CARL

51score
Recommendation
HOLD

GMED

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CARL GMED Winner
Net Income -8.70M 537.87M GMED
Operating Income -9.28M 479.82M GMED
ROE -9.4% 11.8% GMED
ROA -7.3% 10.1% GMED
Total Assets 118.77M 5.30B GMED
Cash 73.02M 526.16M GMED
Current Ratio 11.88 4.26 CARL
Free Cash Flow -13.09M 588.77M GMED

Relative Price Performance (Last 90 Days)

CARL 1M: +14.0% · 3M: +36.4% GMED 1M: +1.7% · 3M: -10.8%

Current Technical Phase

CARL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 62

RSI (14): 61.7 · Price: $12.93

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 55

RSI (14): 55.1 · Price: $81.46

Fundamentals Snapshot

Metric CARL GMED
Market Cap
Forward P/E -9.0 15.8
Trailing P/E 18.4
Revenue (TTM)
Revenue Growth 0.6% 0.3%
Gross Margin 0.8% 0.7%
Operating Margin -0.6% 0.2%
EPS -0.97 4.28
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CARL is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.